Business Wire

Vertex Announces National Reimbursement Agreement in France for KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients

Share

Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health Authorities for the cystic fibrosis (CF) medicines KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor and SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. Both medicines will be available for all eligible patients once the agreement has been published in the French Official Journal.

“Today’s announcement represents a major milestone for CF patients in France. Through this national reimbursement agreement, eligible patients 12 years and older now have access to KAFTRIO and SYMKEVI. For those living with CF, we are delighted to have reached this agreement so quickly and that the French Health Authorities have recognized the value of both medicines,” said Ludovic Fenaux, Senior Vice President, Vertex International.

The reimbursement agreement enables broad access to KAFTRIO® for people with CF ages 12 years and older with one F508del mutation and one minimal function mutation. The triple combination therapy will also be reimbursed for patients who are homozygous for the F508del mutation in the CFTR gene, representing a new therapeutic option for treating physicians.In November 2020, the Transparency Commission (TC) of the French National Authority for Health (HAS) granted KAFTRIO® an ASMR 2 rating, which indicates “a significant improvement in medical service rendered.” Of the 250 first-time listing medicines issued in 2019 by the TC, only two received such a rating.

Under the terms of the new reimbursement agreement, SYMKEVI® will be reimbursed for people with CF ages 12 years and older with one F508del mutation and one of the mutations resulting in residual activity (F/RF) of the CFTR protein as listed in the Summary of Product Characteristics (SmPC). It will also be funded for patients who are homozygous for the F508del mutation in the CFTR gene.

About Cystic Fibrosis

Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 80,000 people globally. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test, or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

About KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a Combination With Ivacaftor

KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor 150 mg was developed for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor/tezacaftor/elexacaftor is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface. The latest approved EU licensed indication for ivacaftor/tezacaftor/elexacaftor was supported by positive results of three global Phase 3 studies in people ages 12 years and older with CF: a 24-week Phase 3 study (Study 445-102) in 403 people with one F508del mutation and one minimal function mutation (F/MF), a four-week Phase 3 study (Study 445-103) in 107 people with two F508del mutations (F/F), and a Phase 3 study (Study 445-104) in 258 people heterozygous for the F508del-CFTR mutation and a CFTR gating mutation (F/G) or a residual function mutation (F/RF).

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About SYMKEVI® (tezacaftor/ivacaftor) in Combination With Ivacaftor

Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information including dosing guidance, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Ludovic Fenaux, Senior Vice President, Vertex International in this press release and statements regarding the reimbursement of, availability of and access to KAFTRIO® and SYMKEVI® for certain patients, the estimated number of patients eligible for a CFTR modulator therapy and our beliefs regarding the benefits of our medicines. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company’s development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under the heading “Risk Factors” in Vertex's annual report and in subsequent filings filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com and www.sec.gov. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com
or
617-961-7163

Media:
mediainfo@vrtx.com
or
International: +44 20 3204 5275
or
U.S.: 617-341-6992

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Crayon Announces Collaboration with Microsoft Teams Essentials – a flexible and affordable solution for everyone1.12.2021 17:10:00 CET | Press release

Crayon, a global leader in IT services and innovation, announced today it is collaborating with Microsoft as it expands its Microsoft Teams subscription portfolio with the addition of a new subscription plan called Teams Essentials. The concept is simple: For only $4 a month, small businesses get the entire Teams digital meeting experience without having to subscribe to the whole Microsoft 365 Suite. This means that your company can BYOE – "bring your own email." “Crayon is excited to be together with Microsoft on launch day for Teams Essentials, offering our partners the ability to order this solution today,” said Crayon CEO Melissa Mulholland. "Microsoft 365 has a complete solution for the digital workplace, but adopting and using the entire suite doesn't necessarily work for all companies. This plan provides easy and affordable access to the core meeting and calling functionalities in Teams." The solution fits perfectly for Crayon’s 7,500 channel partners, enabling them to deliver a

Global Payments Leader, Credorax, Rebrands As ‘Finaro’1.12.2021 17:03:00 CET | Press release

Leading smart payments provider and merchant acquiring bank, Credorax, has today announced its new company identity, Finaro. Focusing on its core pillars of creating multi-dimensional solutions to simplify payments and going the extra mile for its merchants, Finaro empowers global commerce by providing the ideal solution for cross-border businesses with its cutting-edge technology and superior support. The news of the rebranding bookends a strong 2021, with Finaro’s impressive 40% Year-on-Year Compound Annual Growth Rate. Founded in 2009, the company currently employs over 350 people, and is based in Israel and Malta, with presence in China Mainland, Hong Kong, the United States and across Europe. Credorax has already been proven as a payments provider that facilitates its merchants’ growth and with the global fintech industry expected to skyrocket to $190bn by 2026, this rapidly accelerating trajectory creates the perfect environment for Finaro’s new brand to establish itself as a str

Jetcraft Releases 5-year Pre-Owned Market Forecast Exploring New Era for Business Aviation1.12.2021 17:00:00 CET | Press release

Jetcraft, the world leader in business jet sales and acquisitions, is releasing its 5-Year Pre-Owned Business Aviation Market Forecast, introducing an enhanced data-driven methodology recognizing potential market opportunities and incorporating a greater number of global trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005802/en/ Jetcraft’s Owner and Chairman of the Board, Jahid Fazal-Karim (Photo: Business Wire) Jetcraft’s 2021 Market Forecast predicts pre-owned aircraft transaction volume and value will maintain their current healthy growth rates, reaching 2,647 transactions valued at $12.4B annually by 2025. Jahid Fazal-Karim, Owner and Chairman of the Board at Jetcraft, says: “Since the pandemic, the true benefits of business aviation have been realized, particularly by new entrants who have had the means to fly privately but never previously the inclination, and we have seen our industry thrive. “The combina

Neustar Security Services Spins Out with Focused Investment to Foster Accelerated Growth1.12.2021 15:46:00 CET | Press release

Neustar Security Services, LLC (“Neustar Security Services”), a leading global provider of cloud-oriented security services that enable global business to thrive online, has become the newest portfolio company of Golden Gate Capital and GIC following the completed sale of Neustar Inc.’s (“Neustar”) Marketing, Risk and Communications solutions businesses to TransUnion. The spin out marks Neustar Security Services’ entry into its next phase of growth with the focused backing of its investors and strong continuity of leadership. Brian McCann, who has served as President of Neustar’s Security business since 2019, has been appointed CEO of Neustar Security Services and will lead the company’s more than 250 employees. Neustar President and CEO, Charlie Gottdiener, will serve as a Director on the Neustar Security Services Board of Directors. In addition to McCann, the Company’s senior leadership team will include Anthony Chadd, Senior Vice President and Chief Revenue Officer; Carlos Morales,

Dominik Belloin Joins biolog-id’s Board of Directors1.12.2021 15:32:00 CET | Press release

Biolog-id, a global leader in the traceability of sensitive therapeutic products, has just co-opted Dominik BELLOIN within the company’s board. He will sit alongside Pierre Lesourd, Jean-Louis Colders, Jacques Simonnet and Jean-Claude Mongrenier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005699/en/ Dominik Belloin joins biolog-id's board of directors (Photo: Business Wire) Graduated from ESSEC and Harvard Business School (MBA), Dominik Belloin began his career at Goldman Sachs in 1987 in New York City, then in London as Associate and then Executive Director of Corporate Finance. He then joined the Bertelsmann Group where he held several senior management positions before becoming CFO of the RTL Group in Luxembourg. In 2000, he was appointed Managing Director of Merrill Lynch with responsibility for investment banking for the media sector in Europe. In 2003, Dominik Belloin became a member of the Executive Committe

Apave, ESI Group and Onet Technologies – A unique alliance for an outstanding EPR project at the Jaitapur site in India1.12.2021 15:15:00 CET | Press release

Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211201005681/en/ (Photo: Business Wire) Apave, ESI Group (Paris:ESI) and Onet Technologies have formalized, at the WNE (World Nuclear Exhibition) 2021, their collaboration, through the MINS (Make in India Nuclear supply chain Support) alliance, to build a common value proposition in order to respond to the project to create six EPR reactors on the Jaitapur site in western India. Philippe Maillard, CEO of APAVE Group, Emmanuel Leroy, EVP Product, Innovation & Industry Solutions of ESI Group and Alain Gauvin, CEO of ONET Technologies, signed today at WNE 2021, with the participation of Xavier Ursat, Group Senior Executive Vice President, New Nuclear Projects and Engineering, a joint declaration of intent structuring the MINS alliance, thus combining their skills on the outstanding Indian EPR market at the Jaitapur site. A unique Indian project In April 2021, EDF s

Aurora Accelerates Development of the Aurora Driver with AWS1.12.2021 15:00:00 CET | Press release

Today, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), announced that Aurora (NASDAQ: AUR), a leader in self-driving vehicle technology, has selected AWS as its preferred cloud provider for machine learning training and cloud-based simulation workloads. Aurora uses AWS’s proven infrastructure and unparalleled portfolio of capabilities to safely accelerate the development of the Aurora Driver, its scalable self-driving vehicle technology. The Aurora Driver consists of sensors that perceive the world, software that plans a safe path through it, and a computer that powers and integrates Aurora’s hardware and software with any vehicle platform. For its machine learning training and cloud-based simulation workloads, Aurora is all-in on AWS, and it uses the cloud to process trillions of data points each day. Now, the company is scaling its training workloads in the cloud to complete up to 12 million physics-based driving simulations per day by the end of the year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom